ProNAi Therapeutics Inc. (DNAI) will be presenting interim results from its phase II trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma at the 52nd Annual Meeting of the American Society of Clinical Oncology on June 6, 2016.
from RTT - Biotech http://ift.tt/1stMmb4
via IFTTT
No comments:
Post a Comment